PT  - JOURNAL ARTICLE
AU  - A. Omame
AU  - C. U. Nnanna
AU  - S. C. Inyama
TI  - Optimal Control and Cost-effectiveness Analysis of an HPV-Chlamydia Trachomatis co-infection model
AID  - 10.1101/2020.09.07.20190025
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.07.20190025
4099  - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20190025.short
4100  - http://medrxiv.org/content/early/2020/09/09/2020.09.07.20190025.full
AB  - In this work, a co-infection model for human papillomavirus (HPV) and Chlamydia trachomatis with cost-effectiveness optimal control analysis is developed and analyzed. The disease-free equilibrium of the co-infection model is shown not to be globally asymptotically stable, when the associated reproduction number is less unity. It is proven that the model undergoes the phenomenon of backward bifurcation when the associated reproduction number is less than unity. It is also shown that HPV re-infection (εp ≠ 0) induced the phenomenon of backward bifurcation. Numerical simulations of the optimal control model showed that: (i) focusing on HPV intervention strategy alone (HPV prevention and screening), in the absence of Chlamydia trachomatis control, leads to a positive population level impact on the total number of individuals singly infected with Chlamydia trachomatis, (ii) Concentrating on Chlamydia trachomatis intervention controls alone (Chlamydia trachomatis prevention and treatment), in the absence of HPV intervention strategies, a positive population level impact is observed on the total number of individuals singly infected with HPV. Moreover, the strategy that combines and implements HPV and Chlamydia trachomatis prevention controls is the most cost-effective of all the control strategies in combating the co-infections of HPV and Chlamydia trachomatis.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols http://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Federal University of Technology Owerri, NigeriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeswww.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm http://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm